iShares MSCI Indonesia ETF (EIDO) Stock Price Today
Aura AI Summary
Key Stats
- $401.97MMarket Cap
- 1,675,997Volume
- -Sector
- $19.2252W High
- $9.6152W Low
- 78 DaysTypical Hold Time
- -Enterprise Value
- -Div Yield
- 96% Sell | 4% BuyTrading Activity
Track iShares MSCI Indonesia ETF (EIDO) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, iShares MSCI Indonesia ETF has traded between a low of $9.61 and a high of $19.22, highlighting its annual price range. Buy and sell iShares MSCI Indonesia ETF shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Most Recent News
Presidio named Global Innovation Partner of the Year at Cisco Partner Summit 2026
At the Cisco Partner Summit 2026, Presidio was honored as the Global Innovation Partner of the Year, recognizing its outstanding innovation and success in delivering impactful customer solutions. This award highlights Presidio's commitment to partner...

Presidio named Global Services and Software Excellence Partner of the Year at Cisco Partner Summit 2026
Presidio was awarded the Global Services and Software Excellence Partner of the Year at the Cisco Partner Summit 2026. This award recognizes Presidio's outstanding innovation and success in delivering solutions that help customers achieve meaningful ...

Onco360 named national pharmacy partner for AstraZeneca's lung cancer drug Zegfrovy.
Onco360, a leading independent specialty pharmacy, has been selected by AstraZeneca as a national pharmacy partner for Zegfrovy (sunvozertinib), a treatment for advanced non-small cell lung cancer with EGFR exon 20 insertion mutations. Zegfrovy has s...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.